After Tandem Diabetes Care (TNDM) stated earlier today that UnitedHealthcare (UNH) is no longer allowing patients a choice for durable insulin pumps, Leerink analyst Danielle Antalffy said she believes the impact of this decision is "de minimis" for both Insulet (PODD) and DexCom (DXCM) and that the selloffs in their shares was overdone. Top distributors say UnitedHealth reimbursement for Insulet is already difficult to get, while the type of DexCom devices impacted make up a very small percentage of its total installed base, Antalffy tells investors. The big question, however, is whether other payors follow suit, the analyst said. Additionally, Antalffy said the news is an incremental positive for Medtronic (MDT), which was named UnitedHealthcare's preferred, in-network provider of insulin pumps, and an incremental negative for Johnson & Johnson (JNJ).

Reports Q1 revenue $21.4B, consensus $21.4B. "Johnson & Johnson's solid first quarter performance reflects our sharpened focus and the progress in our portfolio and pipeline," said Joaquin Duato, Chairman and Chief Executive Officer. "Our impact across the full spectrum of healthcare is unique in our industry, and the milestones achieved this quarter reinforce our position as an innovation powerhouse."

Healthcare Services Analyst Fidel holds a group luncheon investor meeting with SVP Sopcak in New York on April 18 at 12 pm hosted by Stephens.

Notable companies reporting before tomorrow's open, with earnings consensus, include UnitedHealth (UNH), consensus $6.21... Johnson & Johnson (JNJ), consensus $2.47... Bank of America (BAC), consensus 72c... Morgan Stanley (MS), consensus $1.66... PNC Financial (PNC), consensus $3.02... BNY Mellon (BK), consensus $1.19.

Shares of health care facilities and managed care are in the spotlight on Monday after Florida announced late on Friday five winners of six-year Medicaid managed care contracts. Among the winners... To see the rest of the story go to thefly.com. See Story Here